A Phase 2b Randomized Evaluate the Efficacy , Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis.
The combination of guselkumab and golimumab (currently known as JNJ-78934804) works by blocking both IL-23 and TNF. The combination of guselkumab and golimumab is not yet approved for use in treating any disease, including ulcerative colitis. This combination has been studied in ulcerative colitis and is currently being studied in psoriatic arthritis.
The purpose of the DUET-UC study is to see if the combination of guselkumab and golimumab is safe and effective for treating participants with moderately to severely active ulcerative colitis. Treatment with three different doses of the combination will be compared against treatment with guselkumab or golimumab alone (i.e., not in combination).
You may be eligible for the study if you meet the following criteria.
Please contact CDH Research Institute on 07 5408 0900 for additional information or use the email link below. You can also share details of this study to social media via the links below?
Clinical trials are important because they serve as the foundation for most medical advances.
